dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:29:49Z
dc.date.accessioned2022-10-05T18:53:29Z
dc.date.available2014-05-27T11:29:49Z
dc.date.available2022-10-05T18:53:29Z
dc.date.created2014-05-27T11:29:49Z
dc.date.issued2013-07-01
dc.identifierToxicon, v. 69, p. 50-54.
dc.identifier0041-0101
dc.identifier1879-3150
dc.identifierhttp://hdl.handle.net/11449/75780
dc.identifier10.1016/j.toxicon.2013.01.003
dc.identifierWOS:000320836100008
dc.identifier2-s2.0-84878478208
dc.identifier2-s2.0-84878478208.pdf
dc.identifier5518720125698768
dc.identifier8084974543029515
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3924703
dc.description.abstractBasic research is fundamental for discovering potential diagnostic and therapeutic tools, including drugs, vaccines and new diagnostic techniques. On this basis, diagnosis and treatment methods for many diseases have been developed. Presently, discovering new candidate molecules and testing them in animals are relatively easy tasks that require modest resources and responsibility. However, crossing the animal-to-human barrier is still a great challenge that most researchers tend to avoid. Thus, bridging this current gap between clinical and basic research must be encouraged and elucidated in training programmes for health professionals. This project clearly shows the challenges faced by a group of Brazilian researchers who, after discovering a new fibrin sealant through 20 years of painstaking basic work, insisted on having the product applied clinically. The Brazilian government has recently become aware of this challenge and has accordingly defined the product as strategic to the public health of the country. Thus, in addition to financing research and development laboratories, resources were invested in clinical trials and in the development of a virtual platform termed the Virtual System to Support Clinical Research (SAVPC); this platform imparts speed, reliability and visibility to advances in product development, fostering interactions among sponsors, physicians, students and, ultimately, the research subjects themselves. This pioneering project may become a future model for other public institutions in Brazil, principally in overcoming neglected diseases, which unfortunately continue to afflict this tropical country. © 2013 Elsevier Ltd.
dc.languageeng
dc.relationToxicon
dc.relation2.352
dc.relation0,692
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectFibrin sealant
dc.subjectGAP
dc.subjectTranslational potential
dc.subjectTranslational research
dc.subjectfibrin glue
dc.subjectvaccine
dc.subjectbasic research
dc.subjectbiomedicine
dc.subjectBrazil
dc.subjectclinical research
dc.subjectdiagnostic procedure
dc.subjectdrug design
dc.subjectdrug development
dc.subjecteducation program
dc.subjectfunding
dc.subjecthealth practitioner
dc.subjecthuman
dc.subjectinformation processing
dc.subjectneglected disease
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjecttoxinology
dc.subjecttranslational research
dc.subjecttropics
dc.subjectAnimalia
dc.titleA success in Toxinology translational research in Brazil: Bridging the gap
dc.typeArtigo


Este ítem pertenece a la siguiente institución